LCTXHealthcare · BiotechnologyThe 7 Wall Street analysts covering Lineage Cell Therapeutics, Inc. hold a median 12-month price target of $4.5 — +332.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Lineage Cell Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (82): The share price has been relatively steady.
Issuance (31): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LCTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +332.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 May 2026 | D. Boral Capital | Maintains | Buy | — |
| 28 Apr 2026 | Canaccord Genuity | Initiates | Buy | — |
| 25 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 25 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 5 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 23 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 23 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Mar 2025 | B. Riley Securities | Maintains | Buy | — |
| 11 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 11 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 11 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LCTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Lineage Cell Therapeutics, Inc. returned −39.9% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 9% of US stocks
Cheaper than 22% of US stocks
Cheaper than 84% of US stocks
Higher than 4% of US stocks
Higher than 8% of US stocks
Higher than 99% of US stocks
Higher than 6% of US stocks
Higher than 2% of US stocks
Higher than 19% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lineage Cell Therapeutics, Inc. has a market value of $260.5M and an enterprise value of $210.8M.
Revenue in the twelve months to 30 June 2026: $13.1M. The latest quarter shrank 61.3% year on year.
Net income over the same four quarters: −$32.1M, a −245.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$24.4M.
Lineage Cell Therapeutics, Inc. spent $41K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −3.7×; forward P/E: −7.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lineage Cell Therapeutics, Inc. employs 72 people — $182K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lineage Cell Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lineage Cell Therapeutics provided an update on ReSonance (ANP1), its internally developed cell transplant program for hearing loss, which uses the company’s AlloSCOPE manufacturing platform.
Why it matters — The update concerns a company-developed program being advanced for hearing loss under a research collaboration.
Lineage Cell Therapeutics announced the issuance of a patent underlying its AlloSCOPE 5D manufacturing platform. The announcement was made via Business Wire from the company's Carlsbad, California headquarters.
Why it matters — A patent covering the AlloSCOPE 5D platform helps protect the company's manufacturing technology, an important element of its cell-therapy operations.
Lineage Cell Therapeutics reported progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs. Roche and Genentech continue optimization work on surgical delivery for the company's lead OpRegen program.
Why it matters — LCTX watchers would care because the call confirms continued pipeline advancement and ongoing partner work on the lead OpRegen program, signaling development momentum across multiple cell-therapy candidates.
Lineage Cell Therapeutics, Inc. (LCTX) held its Q2 2026 earnings call, and a transcript of that call has been published on Seeking Alpha. The transcript covers the company's quarterly financial and operational update.
Why it matters — LCTX watchers would find the earnings call transcript a primary source for management's latest commentary on the company's performance and outlook.
Lineage Cell reported a second-quarter loss of $0.03 per share, matching the Zacks Consensus Estimate but wider than the $0.01 per share loss a year earlier, while revenue lagged consensus estimates.
Why it matters — A LCTX watcher would care because the widened quarterly loss and revenue that fell short of estimates signal weaker-than-expected recent financial performance.
The 7 Wall Street analysts covering Lineage Cell Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $3 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Lineage Cell Therapeutics, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lineage Cell Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Lineage Cell Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (82 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +332.7% from the last close, and Ticker Nerd's factor model ranks Lineage Cell Therapeutics, Inc. 61 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lineage Cell Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LCTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $9 over the next 12 months.
Lineage Cell Therapeutics, Inc. returned -39.9% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or off-the-shelf, cell therapies for serious medical conditions.
The most recent item we track (Business Wire, 29 Oct 2026): "Lineage Provides Update on ReSonance® Program for Hearing Loss". Lineage Cell Therapeutics provided an update on ReSonance (ANP1), its internally developed cell transplant program for hearing loss, which uses the company’s AlloSCOPE manufacturing platform.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or off-the-shelf, cell therapies for serious medical conditions. Its current programs center on cell replacement therapies for ophthalmology, neurology, hearing loss, and corneal disease, with product candidates designed to restore or replace damaged cells in targeted tissues. The company’s pipeline includes OpRegen for retinal disorders, OPC1 for spinal cord injury, COR1 for corneal endothelial disease, and other platform-based programs supported by its proprietary manufacturing and delivery capabilities. Lineage Cell Therapeutics, Inc. works at the intersection of regenerative medicine and specialty therapeutics, addressing areas of high unmet medical need through pluripotent stem cell-based technologies.
CEO Mr. Brian M. Culley M.A., M.B.A. · 72 employees · United States · https://www.lineagecell.com
